,大家一定要支持一下这样的新锐//@狸哥很懒:回复@雪球活动:#2023雪球嘉年华# #2023雪球奖#还剩两天了,要是输了还是挺没面子的,拜拜票吧。请老朋友们支持下哈。新锐榜拉到最下面。谢谢!@fo...查看全文
牛唐2023-05-18 16:54
医药板块速评(2022.05.17)
1、医药大型并购受阻,哪些公司有抄底机会?
2、辉瑞投资的哪些公司值得关注?
3、$里格尔制药(RIGL)、$蔚来(NIO)$ 、$Shopify Inc.(SHOP)$ 、$Bausch Health(BHC)、$Grab Holdings(GRAB)等期权异动,后续走势如何看?
$爱奇艺(IQ)$查看全文
牛唐2022-12-06 17:39
医药板块速评(2022.12.05)
1、$里格尔制药(RIGL)药物获批,是否有潜力成为新的并购标的?
2、$Iovance(IOVA)$ 董事买入6500万美元的股票,是否开启新一轮上涨?
3、$阿里巴巴-SW(09988)$ 、$台积电(TSM)$ 等期权异动,后续走势如何看?查看全文
SeekingBiotech2022-12-02 21:30
$里格尔制药(RIGL)$ IDH1获批
RIGL FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation查看全文
产业链观察2022-11-02 21:06
#药闻简讯# $里格尔制药(RIGL)$ 宣布Fostamatinib福斯塔马替尼治疗高风险住院新冠肺炎患者的FOCUS 3期临床试验的一线结果:"该试验接近但未达到主要终点的统计学意义"
新冠重症药物开发难度极大,风险极高。#全球新冠肺炎药物研发竞赛#查看全文
SeekingBiotech2022-11-02 07:06
Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients,失败$里格尔制药(RIGL)$查看全文
产业链观察2022-10-11 05:15
药闻▶$里格尔制药(RIGL)$:基于FDA对福斯塔马替尼Fostamatinib的FORWARD三期试验数据重新分析的审查指导,Rigel预计不会为该适应症提交sNDA。同时宣布裁员16%查看全文
里格尔制药(RIGL)03-02 08:25
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000848 Size: 8 KB 网页链接查看全文
里格尔制药(RIGL)03-02 08:25
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000851 Size: 8 KB 网页链接查看全文
里格尔制药(RIGL)03-06 05:15
$里格尔制药(RIGL)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-24-002475 Act: 34 Size: 12 MB 网页链接查看全文
智通财经APP获悉,Rigel制药公司(RIGL.US)周四表示,该公司用于治疗复发或难治性(R/R)急性髓系白血病(AML)患者的Rezlidhia(olutasidenib)胶囊已获美国食品药品监督管理局批准。Rigel称,这一批准得到了2期试验数据的支持。受此消息影响... 网页链接
智通财经APP获悉,H.C. Wainwright分析师Joseph Pantginis将Rigel Pharmaceuticals(RIGL.US)的目标价从8美元上调至11美元,维持“买入”评级。该公司此前公布了治疗COVID-19住院患者的Tavalisse (fostamatinib)的2期临床试验的积极结果... 网页链接
$里格尔制药(RIGL)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-24-002475 Act: 34 Size: 12 MB 网页链接
$里格尔制药(RIGL)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-031010 Act: 34 Size: 435 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000848 Size: 8 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000850 Size: 8 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000849 Size: 8 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000851 Size: 8 KB 网页链接
$里格尔制药(RIGL)$ 8-K Current report, items 1.01 and 2.01 Accession Number: 0001104659-24-026338 Act: 34 Size: 204 KB 网页链接
$里格尔制药(RIGL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001234 Act: 34 Size: 90 KB 网页链接
$里格尔制药(RIGL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-021843 Act: 34 Size: 13 KB 网页链接
$里格尔制药(RIGL)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000895421-24-000137 Act: 34 Size: 17 KB 网页链接